MPN patients show higher mortality with COVID-19 ‘ruxolitinib discontinuation syndrome’

Patients with myeloproliferative neoplasms (MPN) face a higher mortality risk from COVID-19 infections than the general population, according to a new study. The findings, published in Nature, also show that patients who discontinued ruxolitinib therapy had a ‘striking’ increase in risk of death compared to patients who continued taking the drug. Prior to this, there ...

Already a member?

Login to keep reading.

© 2021 the limbic